US Edition
Prothena Corporation Plc (PRTA) Stock Analysis: Exploring A Biotech With A 277.40% Upside Potential
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Prothena Corporation Plc (PRTA) Stock Analysis: Exploring A Biotech With A 277.40% Upside Potential
Prothena Corporation plc (NASDAQ: PRTA), a biotechnology company situated in Dublin, Ireland, is garnering significant attention in the healthcare sector. Specializing in developing therapies for diseases caused by protein dysregulation, Prothena stands out with its ambitious pipeline and robust collaborations. Despite its current market cap of $346.38 million and a stock price of $6.435, the company presents a potential upside of 277.40%, accor…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
